A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Public ClinicalTrials.gov record NCT04626635. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
Study identification
- NCT ID
- NCT04626635
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 548 participants
Conditions and interventions
Conditions
Interventions
- REGN7075 Drug
- Cemiplimab Drug
- Platinum-based doublet chemotherapy Drug
- Bevacizumab Drug
- Trifluridine-tipiracil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2020
- Primary completion
- Nov 12, 2026
- Completion
- Mar 4, 2027
- Last update posted
- Jul 1, 2026
2020 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| University of California Los Angeles (UCLA) Medical Center | Los Angeles | California | 90095 | — |
| The Regents of the University of California, San Francisco | San Francisco | California | 94118 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic | Aurora | Colorado | 80045 | — |
| University of Florida Health | Gainesville | Florida | 32608 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| START Midwest - Cancer & Hematology Centers of Western Michigan, PC | Grand Rapids | Michigan | 49546 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| The Stefanie Spielman Comprehensive Breast Center | Columbus | Ohio | 43212 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Sarah Cannon Research Institute - 25th Ave | Nashville | Tennessee | 37203 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Oncology And Hematology | San Antonio | Texas | 78229 | — |
| University of Washington/Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04626635, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04626635 live on ClinicalTrials.gov.